Market Trends of Global HER-2 Negative Breast Cancer Industry
This section covers the major market trends shaping the HER- 2 Negative Breast Cancer Market according to our research experts:
Chemotherapy Is Identified as the Most Lucrative Segment of HER-2 Negative Breast Cancer Market
Chemotherapy is one of the most common and aggressive form of drug therapy that is used to destroy cancerous cell in the body and stops them from further division and growth. Chemotherapy drugs are systemic treatments; the drugs travel through the bloodstream and damage cancer cells throughout the body due to which they have high impact on the cancerous cells. For the treatment of HER2-negative breast cancer, different types of chemotherapy drugs are used, either in combination with others or alone depending upon the past treatments, risk of side effects and other conditions.
The growing burden of HER2-negative breast cancer, availability of chemotherapy drugs and ongoing research and development activities in the area are expected to be major factors, fueling growth in the chemotherapy segments. For instance, according to a research study published in February 2022, titled 'The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomized clinical trials PlanB and SUCCESS C', in most patients with HER2-negative early breast cancer, six cycles of docetaxel/cyclophosphamide (TC6) were found to be equally effective to an anthracycline-containing regimen and to have a much lower incidence of overall grade 3/4 toxicities. Hence, positive result from studies like these are further expected to increase the awareness and adoption of the chemotherapy which is expected to boost segment's growth. Also, as per the above-mentioned source, the recommended adjuvant therapy for HER2-negative early breast cancer is anthracycline/cyclophosphamide-taxane chemotherapy (AC-T) (EBC). Hence, the use of chemotherapy is expected to increase over the forecast period.
With the growing research and development activities in the area, the product approval and pipeline products are increasing by the key players in the market, which is further expected ton have a significant impact on the segment's growth over the forecast period. For instance, in October 2021, the United States FDA approved abemaciclib (Verzenio) in combination with endocrine therapy (either an aromatase inhibitor or tamoxifen) for adjuvant treatment of adult patients with hormone receptor (HR)-positive, HER2-negative breast cancer at high risk of recurrence and a Ki-67 score 20%, as determined by an FDA approved test.
Therefore, owing to the new product approvals and ongoing research and development activities, the chemotherapy segment is expected to growth over the forecast period in the studied market.
North America is Expected to Hold a Significant Share in the Market with Similar Trend in the Forecast Period
North America is expected to hold a significant market share in the global HER-2 negative breast cancer market owing to better healthcare infrastructure, and a growing number of foundations and independent venture groups supporting the biopharmaceutical manufacturers.
The presence of significant manufacturers across the different states, and getting funding from various venture partners drive the market related to HER-2 negative breast cancer. For instance, according to the data published by the Organization for Economic Co-operation and Development (OECD), in June 2022, United States healthcare spending was 17.8% of the total gross domestic product (GDP) of the United States in 2021.
Additionally, as per the data published by the Centers for Medicare & Medicaid Services, in March 2022, titled 'CMS Office of the Actuary Releases 2021-2030 Projections of National Health Expenditures', it has been observed that the annual growth in national health spending is expected to be average 5.1% over 2021-2030. Thus, the increasing health spending is expected to increase the availability of technologically advanced therapies and systems to treat HER-2 negative breast cancer cases among the population, thereby propelling the market growth.
While the increasing product launches and developments are further propelling regional growth. For instance, in October 2021, the Food and Drug Administration approved Eli Lilly's Verzenio (abemaciclib), a CDK 4/6 inhibitor, with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. Also, In April 2021, the Food and Drug Administration (FDA) granted regular approval to sacituzumab govitecan (Trodelvy) for some patients with triple-negative breast cancer (TNBC).
Furthermore the increasing cases of HER-2 negative breast cancer is driving the regional growth. For instance, according to the January 2022 update by breastcancer.org, around 1 in 8 women in the country (about 13%) develop invasive breast cancer over their lifetime. These high cases of breast cancer will have a positive impact on the usage of treatment options that help in the market growth. According to the 2022 statistics published by Breastcancer.org, an estimated 287,850 new cases of invasive breast cancer and 51,400 new cases of non-invasive (in situ) breast cancer are expected to be diagnosed in the United States, in 2022. Thus, owing to the rising prevalence of breast cancer, the use of treatment options is increasing which is anticipated to boost the market growth over the forecast period.
Therefore, owing to the aforementioned factors, the studied market is expected to grow over the forecast period.
